J&J's Guselkumab Nears Crowded EU Psoriasis Market After CHMP OK
Executive Summary
Janssen-Cilag/MorphoSys's potential first-in-class psoriasis therapy has received a positive approval recommendation from Europe's top scientific advisory panel, and could become a blockbuster product despite the cluttered and changeable state of the dermatology sector.
You may also be interested in...
MorphoSys CEO Says Strategy To Build Proprietary Pipeline 'On Track'
MorphoSys CEO Simon Moroney tells Scrip that sales of Tremfya in the US and now Europe as a treatment for plaque psoriasis will help fund the German biotech's nascent proprietary pipeline.
Pharma Q3 Results Preview: J&J, Roche Set The Scene
Most of the big pharma companies will report their third-quarter results over the next three weeks. As usual, Johnson & Johnson and Roche will get out of the blocks early on. Scrip considers what to expect from the two front-runners, in the first of our regular financial results previews.
Pharma Q3 Results Preview: J&J, Roche Set The Scene
Most of the big pharma companies will report their third-quarter results over the next three weeks. As usual, Johnson & Johnson and Roche will get out of the blocks early on. Scrip considers what to expect from the two front-runners, in the first of our regular financial results previews.